Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019
PubMed
Article
Google Scholar
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123–1133. https://doi.org/10.1016/j.jacc.2013.11.053
PubMed
Article
Google Scholar
2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC (2016). Eur J Heart Fail. doi:https://doi.org/10.1002/ejhf.592
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, DK MG, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB (2016) Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133(4):447–454. https://doi.org/10.1161/cir.0000000000000366
PubMed
Article
Google Scholar
Castelli G, Fornaro A, Ciaccheri M, Dolara A, Troiani V, Tomberli B, Olivotto I, Gensini GF (2013) Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Heart Fail 6(5):913–921. https://doi.org/10.1161/circheartfailure.112.000120
PubMed
Article
Google Scholar
Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292(3):344–350. https://doi.org/10.1001/jama.292.3.344
CAS
PubMed
Article
Google Scholar
Leening MJ, Siregar S, Vaartjes I, Bots ML, Versteegh MI, van Geuns RJ, Koolen JJ, Deckers JW (2014) Heart disease in the Netherlands: a quantitative update. Neth Heart J 22(1):3–10. https://doi.org/10.1007/s12471-013-0504-x
CAS
PubMed
Article
Google Scholar
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131(1):34–42. https://doi.org/10.1161/circulationaha.114.013255
CAS
PubMed
Article
Google Scholar
Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6(3):606–619. https://doi.org/10.1161/HHF.0b013e318291329a
CAS
PubMed
PubMed Central
Article
Google Scholar
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29(11):1377–1385. https://doi.org/10.1093/eurheartj/ehn153
PubMed
Article
Google Scholar
Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34(1):29–34
CAS
PubMed
Article
Google Scholar
Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryden L (2005) The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28(3):612–616
PubMed
Article
Google Scholar
Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC (1996) Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and registry. Am J Cardiol 77(11):1017–1020
CAS
PubMed
Article
Google Scholar
Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT (2013) Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 10(4):330–336. https://doi.org/10.1177/1479164112471064
PubMed
Article
Google Scholar
Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132(10):923–931. https://doi.org/10.1161/circulationaha.114.014796
PubMed
Article
Google Scholar
Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M (2013) Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 15(2):194–202. https://doi.org/10.1093/eurjhf/hfs153
CAS
PubMed
Article
Google Scholar
The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302. https://doi.org/10.1056/nejm199108013250501
Article
Google Scholar
The effect of digoxin on mortality and morbidity in patients with heart failure (1997). N Engl J Med 336 (8):525–533. doi:https://doi.org/10.1056/nejm199702203360801
Abdul-Rahim AH, MacIsaac RL, Jhund PS, Petrie MC, Lees KR, McMurray JJ (2016) Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. Int J Cardiol 209:310–316. https://doi.org/10.1016/j.ijcard.2016.02.074
PubMed
Article
Google Scholar
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Effect of metoprolol CR/XL in chronic heart failure: (1999). Lancet 353 (9169):2001–2007
Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J (2005) Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149(1):159–167. https://doi.org/10.1016/j.ahj.2004.05.056
CAS
PubMed
Article
Google Scholar
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362(9386):759–766
CAS
PubMed
Article
Google Scholar
Komajda M, Tavazzi L, Francq BG, Bohm M, Borer JS, Ford I, Swedberg K (2015) Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 17(12):1294–1301. https://doi.org/10.1002/ejhf.347
CAS
PubMed
Article
Google Scholar
Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885. https://doi.org/10.1016/s0140-6736(10)61198-1
CAS
PubMed
Article
Google Scholar
Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62(17):1585–1593. https://doi.org/10.1016/j.jacc.2013.04.086
CAS
PubMed
Article
Google Scholar
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492
CAS
PubMed
Article
Google Scholar
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077
PubMed
Article
CAS
Google Scholar
Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9(1). https://doi.org/10.1161/circheartfailure.115.002560
Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30(11):2773–2778. https://doi.org/10.2337/dc07-0717
CAS
PubMed
Article
Google Scholar
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289. https://doi.org/10.1016/s0140-6736(05)67528-9
CAS
PubMed
Article
Google Scholar
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257. https://doi.org/10.1056/NEJMoa1509225
CAS
PubMed
Article
Google Scholar
Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA) (2015). Presented at the European Society of cardiology annual meeting London, UK, 2015
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1603827
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—a long term follow-up (2016). Presented at the European Association of the Study of Diabetes annual meeting, Munich, Germany, 2016
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385(9982):2067–2076. https://doi.org/10.1016/s0140-6736(14)62225-x
CAS
PubMed
Article
Google Scholar
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335. https://doi.org/10.1056/NEJMoa1305889
CAS
PubMed
Article
Google Scholar
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mozenson O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. https://doi.org/10.1056/NEJMoa1307684
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130(18):1579–1588. https://doi.org/10.1161/circulationaha.114.010389
CAS
PubMed
Article
Google Scholar
McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED (2016) Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1(2):126–135. https://doi.org/10.1001/jamacardio.2016.0103
PubMed
Article
Google Scholar
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1501352
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1504720
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37(19):1526–1534. https://doi.org/10.1093/eurheartj/ehv728
CAS
PubMed
PubMed Central
Article
Google Scholar
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30(6):595–602
CAS
PubMed
Article
Google Scholar
Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25(4):543–567. https://doi.org/10.1210/er.2003-0012
CAS
PubMed
Article
Google Scholar
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405–412
CAS
PubMed
PubMed Central
Article
Google Scholar
Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103(22):2668–2673
CAS
PubMed
Article
Google Scholar
Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A, McGuire DK, Vega GL, Grundy SM, de Lemos JA, Drazner MH (2013) Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging 6(5):800–807. https://doi.org/10.1161/circimaging.113.000532
PubMed
PubMed Central
Article
Google Scholar
Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, Vatten LJ (2016) Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 133(7):639–649. https://doi.org/10.1161/circulationaha.115.016801
PubMed
Article
Google Scholar
Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A (2009) Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 103(1):88–92. https://doi.org/10.1016/j.amjcard.2008.08.035
PubMed
Article
Google Scholar
Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24(7):1266–1271. https://doi.org/10.1161/01.atv.0000131783.74034.97
CAS
PubMed
Article
Google Scholar
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234. https://doi.org/10.1056/nejm199807233390404
CAS
PubMed
Article
Google Scholar
Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841. https://doi.org/10.1056/NEJMoa1008862
CAS
Article
Google Scholar
Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117(15):1945–1954. https://doi.org/10.1161/circulationaha.107.720847
CAS
PubMed
Article
Google Scholar
McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ (2000) Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators Eur Heart J 21(21):1750–1758. https://doi.org/10.1053/euhj.2000.2317
CAS
PubMed
Article
Google Scholar
Sulo G, Igland J, Vollset SE, Nygard O, Ebbing M, Sulo E, Egeland GM, Tell GS (2016) Heart failure complicating acute myocardial infarction; burden and timing of occurrence: a nation-wide analysis including 86 771 patients from the Cardiovascular Disease in Norway (CVDNOR) Project. J Am Heart Assoc 5(1). https://doi.org/10.1161/jaha.115.002667
Kannel WB (2000) Incidence and epidemiology of heart failure. Heart Fail Rev 5(2):167–173. https://doi.org/10.1023/a:1009884820941
CAS
PubMed
Article
Google Scholar
Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99(17):2239–2242
CAS
PubMed
Article
Google Scholar
Adameova A, Dhalla NS (2014) Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 19(1):25–33. https://doi.org/10.1007/s10741-013-9378-7
PubMed
Article
Google Scholar
Chavali V, Tyagi SC, Mishra PK (2013) Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes 6:151–160. https://doi.org/10.2147/dmso.s30968
PubMed
PubMed Central
Article
Google Scholar
Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115(25):3213–3223. https://doi.org/10.1161/circulationaha.106.679597
PubMed
Article
Google Scholar
Bell DS (1995) Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18(5):708–714
CAS
PubMed
Article
Google Scholar
Marwick TH (2006) Diabetic heart disease. Heart 92(3):296–300. https://doi.org/10.1136/hrt.2005.067231
CAS
PubMed
Article
Google Scholar
From AM, Scott CG, Chen HH (2010) The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 55(4):300–305. https://doi.org/10.1016/j.jacc.2009.12.003
PubMed
Article
Google Scholar
Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101(19):2271–2276
CAS
PubMed
Article
Google Scholar
Boyer JK, Thanigaraj S, Schechtman KB, Perez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93(7):870–875. https://doi.org/10.1016/j.amjcard.2003.12.026
PubMed
Article
Google Scholar
Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, Pignonblanc PG, Croisille P, Ovize M, Groisne L, Moulin P, Gillebert TC, Derumeaux G (2011) Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 24(11):1268–1275 e1261. https://doi.org/10.1016/j.echo.2011.07.017
PubMed
Article
Google Scholar
Venskutonyte L, Jarnert C, Ryden L, Kjellstrom B (2014) Longitudinal development of left ventricular diastolic function in patients with type 2 diabetes. Diabetes Care 37(11):3092–3097. https://doi.org/10.2337/dc14-0779
CAS
PubMed
Article
Google Scholar
Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271. https://doi.org/10.1016/j.jacc.2013.02.092
PubMed
Article
Google Scholar
Desai AS (2013) Heart failure with preserved ejection fraction: time for a new approach? J Am Coll Cardiol 62(4):272–274. https://doi.org/10.1016/j.jacc.2013.03.075
PubMed
Article
Google Scholar
Katz AM, Rolett EL (2016) Heart failure: when form fails to follow function. Eur Heart J 37(5):449–454. https://doi.org/10.1093/eurheartj/ehv548
PubMed
Article
Google Scholar
Wikstrand J, Wedel H, Castagno D, McMurray JJ (2014) The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 275(2):134–143. https://doi.org/10.1111/joim.12141
CAS
PubMed
Article
Google Scholar
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial (1999). Lancet 353 (9146):9–13
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651–1658. https://doi.org/10.1056/nejm200105313442201
CAS
PubMed
Article
Google Scholar
Bell DS, Lukas MA, Holdbrook FK, Fowler MB (2006) The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 22(2):287–296. https://doi.org/10.1185/030079906x80459
CAS
PubMed
Article
Google Scholar
Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–1675. https://doi.org/10.1056/NEJMoa010713
CAS
PubMed
Article
Google Scholar
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213. https://doi.org/10.1056/NEJMoa1208799
CAS
PubMed
Article
Google Scholar
O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR (2011) Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol 58(9):915–922. https://doi.org/10.1016/j.jacc.2011.03.057
PubMed
Article
Google Scholar
Poole-Wilson PA (2008) Global differences in the outcome of heart failure: implications for clinical practice. J Am Coll Cardiol 52(20):1649–1651. https://doi.org/10.1016/j.jacc.2008.08.022
PubMed
Article
Google Scholar
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781. https://doi.org/10.1016/s0140-6736(03)14285-7
CAS
PubMed
Article
Google Scholar
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467. https://doi.org/10.1056/NEJMoa0805450
CAS
PubMed
Article
Google Scholar
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392. https://doi.org/10.1056/NEJMoa1313731
CAS
PubMed
Article
Google Scholar
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345. https://doi.org/10.1093/eurheartj/ehl250
CAS
PubMed
Article
Google Scholar
Yamamoto K, Origasa H, Hori M (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15(1):110–118. https://doi.org/10.1093/eurjhf/hfs141
CAS
PubMed
Article
Google Scholar
Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114(5):397–403. https://doi.org/10.1161/circulationaha.106.628347
CAS
PubMed
PubMed Central
Article
Google Scholar
Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA (2000) Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 21(23):1967–1978. https://doi.org/10.1053/euhj.2000.2311
CAS
PubMed
Article
Google Scholar
Bohm M, Pogue J, Kindermann I, Poss J, Koon T, Yusuf S (2014) Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. Eur J Heart Fail 16(3):325–333. https://doi.org/10.1002/ejhf.23
PubMed
Article
CAS
Google Scholar
The SOLVD Investigattors (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327(10):685–691. https://doi.org/10.1056/nejm199209033271003
Article
Google Scholar
Chen MD, Dong SS, Cai NY, Fan MD, Gu SP, Zheng JJ, Yin HM, Zhou XH, Wang LX, Li CY, Zheng C (2016) Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord 16:28. https://doi.org/10.1186/s12872-016-0198-2
PubMed
PubMed Central
Article
CAS
Google Scholar
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386):772–776. https://doi.org/10.1016/s0140-6736(03)14284-5
CAS
PubMed
Article
Google Scholar
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9386):767–771. https://doi.org/10.1016/s0140-6736(03)14283-3
CAS
PubMed
Article
Google Scholar
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334(21):1349–1355. https://doi.org/10.1056/nejm199605233342101
CAS
PubMed
Article
Google Scholar
Haas SJ, Vos T, Gilbert RE, Krum H (2003) Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146(5):848–853. https://doi.org/10.1016/s0002-8703(03)00403-4
CAS
PubMed
Article
Google Scholar
Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A (2007) Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 93(8):968–973. https://doi.org/10.1136/hrt.2006.092379
CAS
PubMed
PubMed Central
Article
Google Scholar
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362(9377):7–13. https://doi.org/10.1016/s0140-6736(03)13800-7
CAS
PubMed
Article
Google Scholar
Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J (2001) Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 142(3):502–511. https://doi.org/10.1067/mhj.2001.117600
CAS
PubMed
Article
Google Scholar
Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR (1994) Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 14(5):514–521
CAS
PubMed
Google Scholar
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure (1996). Control Clin Trials 17 (1):77–97
Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 10(2):155–164
CAS
PubMed
Article
Google Scholar
Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJ, Ahmed A (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 15(5):551–559. https://doi.org/10.1093/eurjhf/hft010
CAS
PubMed
PubMed Central
Article
Google Scholar
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52(11):2288–2298. https://doi.org/10.1007/s00125-009-1470-0
CAS
PubMed
Article
Google Scholar
Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162(5):938–948 e932. https://doi.org/10.1016/j.ahj.2011.07.030
CAS
PubMed
Article
Google Scholar
Vintila VD, Roberts A, Vinereanu D, Fraser AG (2012) Progression of subclinical myocardial dysfunction in type 2 diabetes after 5 years despite improved glycemic control. Echocardiography 29(9):1045–1053. https://doi.org/10.1111/j.1540-8175.2012.01748.x
PubMed
Article
Google Scholar
Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108(23):2941–2948. https://doi.org/10.1161/01.cir.0000103683.99399.7e
PubMed
Article
Google Scholar
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559. https://doi.org/10.1056/NEJMoa0802743
CAS
PubMed
Article
Google Scholar
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1611925
Giamouzis G, Triposkiadis F, Butler J (2010) Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J Card Fail 16(3):207–210. https://doi.org/10.1016/j.cardfail.2009.12.007
CAS
PubMed
Article
Google Scholar
Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28(7):1680–1689
CAS
PubMed
Article
Google Scholar
Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28(10):2345–2351
CAS
PubMed
Article
Google Scholar
Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, Gislason GH (2010) Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53(12):2546–2553. https://doi.org/10.1007/s00125-010-1906-6
CAS
PubMed
Article
Google Scholar
Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6(3):395–402. https://doi.org/10.1161/circheartfailure.112.000162
CAS
PubMed
Article
Google Scholar
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853
Article
Google Scholar
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987
CAS
PubMed
Article
Google Scholar
Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731. https://doi.org/10.1136/bmj.b4731
PubMed
PubMed Central
Article
Google Scholar
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46(2):145–154. https://doi.org/10.1007/s00592-008-0090-3
CAS
PubMed
Article
Google Scholar
McAlister FA, Eurich DT, Majumdar SR, Johnson JA (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10(7):703–708. https://doi.org/10.1016/j.ejheart.2008.05.013
CAS
PubMed
Article
Google Scholar
Vaccaro O, Masulli M, Bonora E, Del Prato S, Nicolucci A, Rivellese AA, Riccardi G (2012) The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care 35(12):e82. https://doi.org/10.2337/dc12-0954
CAS
PubMed
PubMed Central
Article
Google Scholar
Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ (2013) Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 10(4):289–301. https://doi.org/10.1177/1479164112475102
PubMed
Article
CAS
Google Scholar
Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ (2015) Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res 12(3):164–174. https://doi.org/10.1177/1479164115570301
CAS
PubMed
Article
Google Scholar
Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM (2013) Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36(8):2254–2261. https://doi.org/10.2337/dc13-0356
CAS
PubMed
PubMed Central
Article
Google Scholar
Kostev K, Rathmann W (2013) Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010). Prim Care Diabetes 7(3):229–233. https://doi.org/10.1016/j.pcd.2013.03.003
PubMed
Article
Google Scholar
Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Almeras N, Haffner SM, Balkau B, Despres JP (2013) Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA. Diabetes Obes Metab 15(7):629–641. https://doi.org/10.1111/dom.12075
CAS
PubMed
Article
Google Scholar
Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL (2013) Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 98(2):668–677. https://doi.org/10.1210/jc.2012-3042
CAS
PubMed
PubMed Central
Article
Google Scholar
McFarlane SI (2009) Insulin therapy and type 2 diabetes: management of weight gain. J Clin Hypertens (Greenwich, Conn) 11(10):601–607. https://doi.org/10.1111/j.1751-7176.2009.00063.x
CAS
Article
Google Scholar
Gans RO, Bilo HJ, Donker AJ (1996) The renal response to exogenous insulin in non-insulin-dependent diabetes mellitus in relation to blood pressure and cardiovascular hormonal status. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc-Eur Ren Assoc 11(5):794–802
CAS
Article
Google Scholar
Nandish S, Bailon O, Wyatt J, Smith J, Stevens A, Lujan M, Chilton R (2011) Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep 13(2):123–128. https://doi.org/10.1007/s11883-011-0165-4
CAS
PubMed
Article
Google Scholar
Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319–328. https://doi.org/10.1056/NEJMoa1203858
CAS
PubMed
Article
Google Scholar
Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE) (2016) Diabetes. Care 39(5):709–716. https://doi.org/10.2337/dc15-1676
Article
CAS
Google Scholar
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125–2135. https://doi.org/10.1016/s0140-6736(09)60953-3
CAS
PubMed
Article
Google Scholar
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457–2471. https://doi.org/10.1056/NEJMoa072761
CAS
PubMed
Article
Google Scholar
Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370(9593):1129–1136. https://doi.org/10.1016/s0140-6736(07)61514-1
CAS
PubMed
Article
Google Scholar
McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, Ayers CR, Drazner MH, Khera A, de Lemos JA (2010) Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur Heart J 31(18):2262–2270. https://doi.org/10.1093/eurheartj/ehq228
CAS
PubMed
PubMed Central
Article
Google Scholar
McMurray J (2013) The Vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD). Presented at the ESC Heart Failure Congress 2013, May 26, Lisbon Portugal
Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE (2015) Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol 14:57. https://doi.org/10.1186/s12933-015-0215-2
PubMed
PubMed Central
Article
CAS
Google Scholar
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500–508. https://doi.org/10.1001/jama.2016.10260
CAS
PubMed
PubMed Central
Article
Google Scholar
Jorsal A (2016) The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus (LIVE) study. Presented at the ESC Heart Failure Congress 2016, May 24, Florence Italy
Berkelaar M, Eekhoff EM, Simonis-Bik AM, Boomsma DI, Diamant M, Ijzerman RG, Dekker JM, t’Hart LM, de Geus EJ (2013) Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia 56(6):1436–1443. https://doi.org/10.1007/s00125-013-2848-6
CAS
PubMed
Article
Google Scholar
Valensi P, Chiheb S, Fysekidis M (2013) Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia 56(6):1196–1200. https://doi.org/10.1007/s00125-013-2909-x
CAS
PubMed
Article
Google Scholar
Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, Nielsen OW, Haugaard SB, Sajadieh A (2017) Effects of Liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study. Diabetes Care 40(1):117–124. https://doi.org/10.2337/dc16-1580
PubMed
Article
Google Scholar
Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR (2017) Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19(7):926–935. https://doi.org/10.1111/dom.12924
PubMed
PubMed Central
Article
Google Scholar
Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17(12):1180–1193. https://doi.org/10.1111/dom.12572
CAS
PubMed
PubMed Central
Article
Google Scholar
Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28. https://doi.org/10.1186/1475-2840-13-28
PubMed
PubMed Central
Article
CAS
Google Scholar
Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2(9):691–700. https://doi.org/10.1016/s2213-8587(14)70120-2
PubMed
Article
Google Scholar
Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, Broedl UC, Johansen OE (2016) Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 13(2):119–126. https://doi.org/10.1177/1479164115616901
CAS
PubMed
Article
Google Scholar
Kohler S, Salsali A, Hantel S, Kaspers S, Woerle HJ, Kim G, Broedl UC (2016) Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther 38(6):1299–1313. https://doi.org/10.1016/j.clinthera.2016.03.031
CAS
PubMed
Article
Google Scholar
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920
CAS
PubMed
Article
Google Scholar
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597. https://doi.org/10.1161/circulationaha.113.005081
CAS
PubMed
Article
Google Scholar
Rajasekeran H, Lytvyn Y, Cherney DZ (2016) Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89(3):524–526. https://doi.org/10.1016/j.kint.2015.12.038
CAS
PubMed
Article
Google Scholar
Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 59(7):1333–1339. https://doi.org/10.1007/s00125-016-3956-x
PubMed
PubMed Central
Article
Google Scholar
Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39(7):1108–1114. https://doi.org/10.2337/dc16-0330
PubMed
Article
Google Scholar
Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I (2016) Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 15:37. https://doi.org/10.1186/s12933-016-0356-y
PubMed
PubMed Central
Article
CAS
Google Scholar
Ofstad AP, Johansen OE, Gullestad L, Birkeland KI, Orvik E, Fagerland MW, Urheim S, Aakhus S (2014) Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Baerum Cardiovascular Diabetes (ABCD) study. Am Heart J 168(3):280–288.e282. https://doi.org/10.1016/j.ahj.2014.03.026
PubMed
Article
Google Scholar